Freeflow Ventures is hosting a discussion that will focus on portfolio company Entos on Wednesday August 31st at 8am Pacific / 11am Eastern. You can register here and invite others that might be interested.
Entos combines machine learning and automated chemistry to revolutionize small-molecule therapeutics design. Their customers are researchers and leaders in healthcare developing therapies and cures for diseases like cancer. Entos was recently named to Forbes Magazine’s 2022 list of groundbreaking artificial intelligence companies. Learn more about the company at here.
The discussion will kick off with a presentation and introductory remarks from the cofounders, Tom Miller and Fred Manby. It will be followed by a deep dive discussion into the technology and its use cases in human health.
Other articles
October 30, 2024
Holoclara: Developing Allergic and Autoimmune Disease Relief by Using Worms
Holoclara is a Freeflow Fund One portfolio company that discovers, develops and…
October 10, 2024
Membrion: Solving for Wastewater Recovery
Membrion is a Freeflow Fund Two portfolio company led by Founder & CEO Greg…
September 25, 2024
Wild Microbes: Scaling New Bioproducts
Wild Microbes is a Freeflow Fund Two portfolio company founded by Tim Wannier…